FI117042B - Oralt administrerbara farmaceutiska formulat - Google Patents
Oralt administrerbara farmaceutiska formulat Download PDFInfo
- Publication number
- FI117042B FI117042B FI950947A FI950947A FI117042B FI 117042 B FI117042 B FI 117042B FI 950947 A FI950947 A FI 950947A FI 950947 A FI950947 A FI 950947A FI 117042 B FI117042 B FI 117042B
- Authority
- FI
- Finland
- Prior art keywords
- polyvinylpyrrolidone
- raloxifene
- lactose
- cross
- mixture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Claims (8)
1. Oralt administrerbar farmaceutisk komp som omfattar raloxifenhydroklorid tillsammans med 5 aktivt ämne, polyvinylpyrrolidon och ett vattenlös spädningsmedel, kännetecknad av att det ytaktiva ämnet är en sorbitanfettsyrae ler en polyoxietylensorbitanfettsyraester; och det vattenlösliga utspädningsmedlet är po 10 ler socker.
2. Komposition enligt patentkrav 1, känni nad av att det ytaktiva ämnet är en polyoxietyl tanfettsyraester.
3. Komposition enligt patentkrav 1 eller ^ 15 netecknad av att det ytaktiva ämnet är polysor
4. Komposition enligt patentkrav 1 - 3, tecknad av att det vattenlösliga utspädningsm socker.
5. Komposition enligt patentkrav 1-4, 20 tecknad av att det vattenlösliga utspädningsm !*. laktos. .·. 6. Komposition enligt patentkrav 1-5, * tecknad av att den omfattar vidare ett smörjan • ψ · och ett disintegrerande medel. • · /*·* 25 7. Komposition enligt patentkrav 6, känm * * · ••5 2 n a d av att det smöriande medlet är magnesiumste tt· V : ler stearinsyra och det disintegrerande medlet är det polyvinylpyrrolidon.
8. Oralt administrerbar farmaceutisk komp ·*" in 1, „ -.4-+. -J--C _ 4_ ____ 1___· 4Γ__U
10. Komposition enligt patentkrav 9, tecknad av att det disintegrerande medlet är det polyvinylpyrrolidon.
11. Komposition enligt patentkrav 1-9, 5 tecknad av att den vidare omfattar ett filmövei • 1 • · · 9 • 9 9 9 • 999 999 9 9 9 9 9 9 9 999 9 9 9 9 999 9 9 •99 9 9 9 9 99 9 9 99 9 9 9 9 9 9 9 9 9 9 9 9 9 9 '999 9 9 9 9
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20491594A | 1994-03-02 | 1994-03-02 | |
| US20491594 | 1994-03-02 | ||
| SG9700220 | 1997-01-30 | ||
| SG1997000220A SG65636A1 (en) | 1994-03-02 | 1997-01-30 | Orally administrable pharmaceutical formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI950947A0 FI950947A0 (sv) | 1995-03-01 |
| FI950947A FI950947A (sv) | 1995-09-03 |
| FI117042B true FI117042B (sv) | 2006-05-31 |
Family
ID=26665140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI950947A FI117042B (sv) | 1994-03-02 | 1995-03-01 | Oralt administrerbara farmaceutiska formulat |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0670162B1 (sv) |
| JP (1) | JP3574210B2 (sv) |
| CN (1) | CN1098684C (sv) |
| AT (1) | ATE211910T1 (sv) |
| AU (1) | AU684882B2 (sv) |
| BR (1) | BR9500758A (sv) |
| CA (1) | CA2143263C (sv) |
| CZ (1) | CZ286119B6 (sv) |
| DE (1) | DE69524981T2 (sv) |
| DK (1) | DK0670162T3 (sv) |
| ES (1) | ES2166799T3 (sv) |
| FI (1) | FI117042B (sv) |
| HU (1) | HU225418B1 (sv) |
| IL (1) | IL112746A (sv) |
| NO (1) | NO314286B1 (sv) |
| NZ (1) | NZ270588A (sv) |
| PL (1) | PL178858B1 (sv) |
| PT (1) | PT670162E (sv) |
| RU (1) | RU2118540C1 (sv) |
| SG (1) | SG65636A1 (sv) |
| SI (1) | SI0670162T1 (sv) |
| ZA (1) | ZA951497B (sv) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6197789B1 (en) | 1995-06-07 | 2001-03-06 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
| US6458811B1 (en) | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
| CZ300341B6 (cs) * | 1996-03-26 | 2009-04-22 | Eli Lilly And Company | Farmaceutická kompozice obsahující raloxifen |
| CA2219377A1 (en) * | 1996-10-30 | 1998-04-30 | Eli Lilly And Company | Improvements in or relating to the prophylaxis of breast cancer |
| ZA979723B (en) | 1996-10-30 | 1999-07-29 | Lilly Co Eli | Methods of preventing breast cancer. |
| US6117911A (en) * | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| US6413533B1 (en) * | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| WO2001042186A1 (fr) | 1999-12-13 | 2001-06-14 | Chugai Seiyaku Kabushiki Kaisha | Compose a chaine laterale hydroxycarbonyl-halogenoalkyle |
| JP4798924B2 (ja) * | 1999-12-13 | 2011-10-19 | 中外製薬株式会社 | ヒドロキシカルボニル−ハロゲノアルキル側鎖を有する化合物 |
| AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
| PL363311A1 (en) * | 2001-04-24 | 2004-11-15 | Merck Patent Gmbh | Combination therapy using anti-angiogenic agents and tnfalpha |
| AU2003266940B2 (en) | 2002-09-30 | 2007-02-08 | A/S Gea Farmaceutisk Fabrik | Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these |
| US20050008704A1 (en) * | 2003-07-11 | 2005-01-13 | Ray Anup Kumar | Pharmaceutical composition for solubility enhancement of hydrophobic drugs |
| IN2014MN00380A (sv) | 2006-06-30 | 2015-06-19 | Iceutica Pty Ltd | |
| EP2197423B1 (en) * | 2007-10-16 | 2014-12-03 | Pharmathen S.A. | Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof |
| WO2009080364A1 (en) * | 2007-12-21 | 2009-07-02 | Synthon B.V. | Raloxifene composition |
| WO2010121328A1 (en) | 2009-04-24 | 2010-10-28 | Iceutica Pty Ltd | A novel formulation of indomethacin |
| EP2448562B1 (en) * | 2009-07-02 | 2013-11-06 | Synthon B.V. | Raloxifene composition |
| WO2011099942A1 (en) | 2010-02-09 | 2011-08-18 | Silverstone Pharma | New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy |
| CN103006570B (zh) * | 2012-10-08 | 2013-12-25 | 孙维会 | 一种阿佐昔芬速释微丸及其制备方法 |
| DK2925320T3 (da) | 2012-11-30 | 2021-05-10 | Pharmathen Sa | Hidtil ukendt fremgangsmåde til forbedring af bio-tilgængeligheden af lægemidler med lav vandopløselighed |
| CN103830197A (zh) * | 2014-03-14 | 2014-06-04 | 崔书豪 | 一种盐酸雷洛昔芬分散片及其制备方法 |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| KR102612983B1 (ko) * | 2016-09-30 | 2023-12-13 | 한미약품 주식회사 | 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
-
1995
- 1995-02-23 BR BR9500758A patent/BR9500758A/pt not_active Application Discontinuation
- 1995-02-23 CA CA002143263A patent/CA2143263C/en not_active Expired - Lifetime
- 1995-02-23 ZA ZA951497A patent/ZA951497B/xx unknown
- 1995-02-23 IL IL11274695A patent/IL112746A/xx not_active IP Right Cessation
- 1995-02-24 CZ CZ1995499A patent/CZ286119B6/cs not_active IP Right Cessation
- 1995-02-24 RU RU95102924A patent/RU2118540C1/ru not_active IP Right Cessation
- 1995-02-27 CN CN95100822A patent/CN1098684C/zh not_active Expired - Lifetime
- 1995-02-28 DE DE69524981T patent/DE69524981T2/de not_active Expired - Lifetime
- 1995-02-28 ES ES95301291T patent/ES2166799T3/es not_active Expired - Lifetime
- 1995-02-28 PT PT95301291T patent/PT670162E/pt unknown
- 1995-02-28 NZ NZ270588A patent/NZ270588A/en unknown
- 1995-02-28 EP EP95301291A patent/EP0670162B1/en not_active Expired - Lifetime
- 1995-02-28 SI SI9530581T patent/SI0670162T1/xx unknown
- 1995-02-28 AT AT95301291T patent/ATE211910T1/de active
- 1995-02-28 DK DK95301291T patent/DK0670162T3/da active
- 1995-03-01 PL PL95307491A patent/PL178858B1/pl not_active IP Right Cessation
- 1995-03-01 AU AU13548/95A patent/AU684882B2/en not_active Expired
- 1995-03-01 JP JP4177395A patent/JP3574210B2/ja not_active Expired - Lifetime
- 1995-03-01 HU HU9500635A patent/HU225418B1/hu not_active IP Right Cessation
- 1995-03-01 FI FI950947A patent/FI117042B/sv not_active IP Right Cessation
- 1995-03-01 NO NO19950799A patent/NO314286B1/no not_active IP Right Cessation
-
1997
- 1997-01-30 SG SG1997000220A patent/SG65636A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI117042B (sv) | Oralt administrerbara farmaceutiska formulat | |
| US5811120A (en) | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation | |
| US6673369B2 (en) | Controlled release formulation | |
| US20090104263A1 (en) | 5-HT4 partial agonist pharmaceutical compositions | |
| US6462237B1 (en) | Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride | |
| PL217835B1 (pl) | Preparat farmaceutyczny zawierający sól wapniową atorwastatyny, sposób wytwarzania tego preparatu i jego zastosowanie do leczenia hipercholesterolemii i hiperlipidemii | |
| KR20010086062A (ko) | 고가용성 약물용 서방성 메트리스 시스템 | |
| US20140248351A1 (en) | Pharmaceutical composition comprising fesoterodine | |
| CN103054820B (zh) | 一种盐酸决奈达隆药物组合物及其制备方法 | |
| EP2148655B1 (en) | Pharmaceutical compositions of clopidogrel | |
| SK1752001A3 (en) | Pharmaceutical compositions comprising ibuprofen and domperidone | |
| US20050053657A1 (en) | Controlled release formulation of clarithromycin or tinidazol | |
| US20100003319A1 (en) | Raloxifene immediate release tablets | |
| US7105178B2 (en) | Cardiotonic composition | |
| CN102028670A (zh) | 一种包含替米沙坦和钙离子通道拮抗剂的复方胶囊剂 | |
| EP2197423B1 (en) | Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof | |
| TWI730289B (zh) | 氨基吡喃衍生物的組合物 | |
| CN117815197A (zh) | 一种瑞巴派特缓释制剂及其制备方法和应用 | |
| KR100335580B1 (ko) | 경구투여가능한약학제제 | |
| CA2596153A1 (en) | Rimonabant-containing pharmaceutical preparation | |
| AU2007263016A1 (en) | Oral pharmaceutical composition of a poorly water-soluble active substance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 117042 Country of ref document: FI |
|
| MM | Patent lapsed |